[Pubmed] The efficacy and safety between efgartigimod and intravenous immunoglobulin in elderly generalized myasthenia g
Posté : 23 févr. 2025 12:00
Clin Immunol. 2025 Feb 21:110457. doi: 10.1016/j.clim.2025.110457. Online ahead of print.
ABSTRACT
The study examines efgartigimod and intravenous immunoglobulin (IVIg) in elderly patients with generalized myasthenia gravis (GMG), focusing on changes in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores, pyridostigmine dosage, and minimal symptom expression (MSE) over an 8-week period. Among 74 enrolled patients, efgartigimod showed greater reduction in MG-ADL scores compared to IVIg at weeks 4 and 8, with no serious adverse events, suggesting its superior efficacy and safety in elderly Chinese patients with acetylcholine receptor antibody-positive (AChR-Ab(+)) GMG.
PMID:39988290 | DOI:10.1016/j.clim.2025.110457
Source: https://pubmed.ncbi.nlm.nih.gov/3998829 ... t9+e462414